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Yellow fever (YF) is a mosquito-borne viral disease that is endemic in several countries of sub-Saharan Africa and South America. The World
Health Organization estimates that YF causes 200,000 symptomatic cases and 30,000 deaths globally every year, with over 90% of reported cases
and deaths occurring in Sub-Saharan Africa. However, other estimates propose much higher figures particularly in Africa. YF prevention is based
on a vaccine that exist since 1937. This vaccine is derived from a live attenuated strain of YF virus that confers protection against the seven known
YFV genotypes. An important limitation of the currently approved YF vaccines is their manufacture that is a fastidious and lengthy process that
requires inoculation of embryonated eggs. This process has a limited capacity for rapid and high scale production to respond to massive
outbreaks. Additionally, there are reports of the occurrence of fatal YF vaccine-associated disease which point to the need of new easily
manufactured and highly scalable vaccines against YF. Animal models are important to vaccine development. Regarding YF, there are several
animal models including mice, hamsters and non-human primates. The small animal models consist mostly of genetically-deficient inbreed mice
that lack important functions of the immune system. In this work, we are developing a mouse model of YF using the outbreed Swiss Webster
mouse strain.
An Outbreed Mouse Model of Yellow Fever Virus for Study of 
Pathogenesis and Development of Vaccines and Therapeutics
Yakhya Dièye, Moussa Dia, André P. Bédékélabou and Ousmane Faye
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We tested five YFV strains from the collection of the Institut Pasteur de Dakar (Table 1) for their ability to cause disease to Swiss mice after
intraperitoneal administration. Virus stocks prepared from human or insect cell lines were well tolerated by the mice. In contrast, viruses collected
from brain homogenates of newborn mice caused mortality to adult Swiss rodents after intraperitoneal administration (Table 2).
CONCLUSION
METHODS AND RESULTS
BACKGROUND
Figure 1. Strain YF-IPD1 from newborn brain
homogenate is virulent at low doses in adult Swiss
mice. Mice were infected by the intraperitoneal route with
the indicated doses of virus and survival was followed for
21 days.
Figure 3. Exposure to Yellow Fever virus does not protect Swiss mice
against West Nile Virus. Mice survivors of strains YF-IPD 1 and 2 were
challenged 1 month after exposure with Lineages 1 (WNV1) or 7 (Koutango,
KGT) of West Nile virus.
We showed that Yellow Fever virus prepared from brain
homogenates of newborn mice can cause lethal disease
to outbreed Swiss Webster mice. Prior exposure to non-
lethal Yellow Fever virus confer protection against this
challenge. This model could be used to study the
pathogenesis of YF virus and to perform preclinical
development of vaccines and therapeutics for YF.
Figure 2. Pre-exposure to Yellow Fever viruses from
brain homogenates but not from cell lines confer
protection against lethal challenge with strain YF-IPD1.
Mice immunized with the 17D Yellow Fever vaccine strain or
survivors of the strains tested in this study were challenged
one month later with a lethal dose of strain YF-IPD1 and the
survival followed for 21 days.
STRAINS YEAR LOCATION ORIGIN
YF-IPD1 1973 Ivory Coast Mosquito
YF-IPD2 1995 Senegal Mosquito
YF-IPD3 1995 Senegal Mosquito
YF-IPD4 1995 Senegal Mosquito
YF-IPD5 1991 Cameroon Human
Table 1. Characteristics of Yellow Fever Virus strains tested in this study
STRAINS C6-36
(pfu)
BH-High
(pfu)
BH-Low
(pfu)
YF-IPD1 12/12
(5 X 105)
0/9
(5 X 107)
Fig. 1
YF-IPD2 12/12
(3 X 105)
6/12
(1010)
8/8
(5 X 102)
YF-IPD3 12/12
(105)
6/8
(1010)
5/8
(5 X 103)
YF-IPD4 12/12
(105)
6/6
(1010)
6/8
(1,5 X 103)
YF-IPD5 12/12
(105)
6/6
(5 X 105)
4/8
(104)
Mouse survival to low doses of YF-IPD1
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Pre-exposure to viruses from newborn
brain homogenates but not from cell lines
confers protection against lethal YFV challenge
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Exposure to Yellow Fever Virus does not
protect Swiss mice against other flaviviruses
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Table 2. Survival of Swiss mice infected with Yellow Fever viruses
prepared from insect cell lines or from newborn brain homogenates
The numbers in the table show the survivors over the total number of mice tested. C6-36,
insect cell line; BH-High, high doses of virus from brain homogenates; BH-Low, low doses
of virus from brain homogenates.
